Our Partners Empower Us to Success

Dana-Farber Cancer Institute

Transgenomic has licensed a high-sensitivity mutation detection technology called COLD-PCR from the Dana-Farber Cancer Institute (DFCI), Boston, MA. This variation of the standard PCR technology enriches mutations in DNA samples and is a much more sensitive technique for finding low level mutations in tissue and body fluids that are involved with a variety of diseases. COLD-PCR was invented at DFCI by Dr. Mike Makrigiorgos who has demonstrated its effectiveness in enriching for mutations in cancer-related genes in samples where standard DNA sequencing is not sensitive enough to detect these very low concentration somatic DNA mutations. The licensing terms include exclusive rights to commercialize COLD-PCR technology combined with Sanger sequencing as well as all applications for mitochondrial DNA analysis.

Horizon Discovery Group

Horizon Discovery Group plc, the international life science company supplying research tools and services that power genomics research and the development of personalized medicines, and Transgenomic, Inc. announced a new Original Equipment Manufacture (OEM) agreement to incorporate Horizon’s human genomic reference standards, produced by Horizon’s Diagnostics division, into Transgenomic’s Multiplexed ICE COLD-PCR (MX-ICP) kits for use in research and clinical applications. The standards are being used in both quality control and mutation concentration assays.

Transgenomic, Inc. has a research agreement with the University of Melbourne to conduct additional clinical validation studies of its  MX-ICP technology. MX-ICP is a high sensitivity DNA amplification technology that allows the simultaneous detection of multiple mutations in multiple genes from tumor samples or any liquid sample, such as blood or urine. A study will be conducted using DNA isolated from pre-treatment tumor biopsies from patients enrolled in clinical trials. It aims to determine the prevalence and clinical significance of ultra-low frequency mutations that would otherwise go undetected by NGS or Sanger sequencing-based methodologies. In the next phase of the project, Transgenomic expects to conduct further studies with University of Melbourne researchers to validate the use of MX-ICP to accurately detect tumor mutations using blood or plasma.

The MSeqDR Project

Transgenomic is partnering with the scientific community by contributing to the development of  a global mitochondrial variant database in an effort to reclassify variants of unknown significance. This will enhance diagnostic capabilities.

Dravet Syndrome Foundation

The “Consider Dravet” campaign was developed to inform neurologists and pediatricians of the hallmark signs of Dravet syndrome and to promote early diagnosis in young patients who have this syndrome. Transgenomic is the exclusive sponsor of an educational grant that supports
this campaign.

United Mitochondrial Disease Foundation

Transgenomic provides funding for the “Grand Rounds” meetings to help educate health care professionals on the diagnosis and treatment of mitochondrial disease.

Neuropathy Association

Transgenomic held a Web cast on small fiber neuropathy to help educate and inform patients, and the medical community at large, about this condition and the value of genetic testing.